Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients.

Richelsen B, Richelsen B, Pedersen SB, Kristensen K, Børglum JD, Nørrelund H, Christiansen JS, Jørgensen JO

Metabolism: clinical and experimental1 Jul 2000Cited by 60 (Europe PMC)

PMID10910003DOI10.1053/meta.2000.6738PepBankPUB-10910003

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese women, weight loss was similar with GH and placebo during diet restriction: 4.6% versus 4.5%.
In plain wordsIn obese women during diet restriction, weight loss was similar with GH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeWeight loss
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Body weight · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Measurements
Weight loss
4.5%
placebo group
Weight loss
4.6%
GH group
Source sentences
Summary
Weight loss after 4 weeks was similar in the 2 groups, with a reduction of 4.5% (placebo) and 4.6% (GH) and a reduction of FM by 7.4% and 9.0% ([NS] nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000301
02HumanRandomized controlled trialEfficacy outcome
In obese women, fat mass decreased by 9.0% with GH versus 7.4% with placebo, without a significant difference.
In plain wordsIn obese women during diet restriction, fat loss did not differ significantly between GH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeFat mass loss
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Body composition · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Measurements
Fat mass reduction
7.4%
placebo group
Fat mass reduction
9%
GH group
Source sentences
Summary
Weight loss after 4 weeks was similar in the 2 groups, with a reduction of 4.5% (placebo) and 4.6% (GH) and a reduction of FM by 7.4% and 9.0% ([NS] nonsignificant).
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000302
03HumanRandomized controlled trialEfficacy outcome
In obese women during diet restriction, GH had no additional effect on the increase in adipose tissue HSL activity.
In plain wordsIn obese women during diet restriction, GH did not increase adipose tissue HSL activity more than placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeAdipose tissue HSL activity
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Lipid Metabolism · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Source sentences
Summary
AT-HSL activity was significantly enhanced after weight loss, but GH had no additional effect on this minor increment.
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000305
04HumanRandomized controlled trialEfficacy outcome
In obese women during diet restriction, free fatty acid increases were similar with GH and placebo.
In plain wordsIn obese women during diet restriction, free fatty acid increases were similar with GH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeFree fatty acids
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Lipids · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Source sentences
Summary
This is in accordance with the finding that the increment in free fatty acid (FFA) after weight loss was similar in the 2 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000306
05HumanNon-randomized trialEfficacy outcome
In obese women on a very-low-calorie diet, adipose tissue LPL activity fell by 65% +/- 8% in the GH group (P < .01) and by 20% +/- 12% (not significant) in the placebo group.
In plain wordsIn obese women on a very-low-calorie diet, fat-tissue LPL activity fell clearly with GH and only slightly, not significantly, with placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseAdipose tissue LPL activity
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Lipid Metabolism · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Measurements
Adipose tissue LPL activity reduction
65%
GH group, +/-8
Adipose tissue LPL activity reduction
20%
placebo group, +/-12, not significant
Source sentences
Summary
The weight loss resulted in a small and NS reduction of AT-LPL activity by 20% +/- 12% in the placebo group, but in the GH group, AT-LPL was significantly reduced by 65% +/- 8% (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000303
06HumanNon-randomized trialEfficacy outcome
In obese women on a very-low-calorie diet, muscle LPL activity was not affected by weight loss alone but fell by 20.4% +/- 10% in the GH group (P < .05).
In plain wordsIn obese women on a very-low-calorie diet, muscle LPL activity did not change with weight loss alone but fell with GH.
Peptide
HGH (somatotropin)
Outcome
DecreaseMuscle LPL activity
Study
n = 18
Comparator
Placebo with very-low-calorie diet
Outcome group
Lipid Metabolism · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Measurements
Muscle LPL activity reduction
20.4%
GH group, +/-10
Source sentences
Summary
Muscle LPL (M-LPL) activity was not affected by the weight loss alone, but a significant reduction was observed in the GH group (20.4% +/- 10%, P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000304
07HumanNon-randomized trialEfficacy outcome
In obese women during diet restriction, GH treatment was associated with reduced HDL cholesterol (P < .05).
In plain wordsIn obese women during diet restriction, GH treatment was linked to lower HDL cholesterol.
Peptide
HGH (somatotropin)
Outcome
DecreaseHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.04 IU/kg · 4 weeksAs given in this study (human).
Source sentences
Summary
GH treatment was associated with a significant reduction of high-density lipoprotein (HDL) cholesterol (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
A very-low-calorie diet ([VLCD] 740 kcal/d) was given to 18 obese women (body mass index [BMI] > 35 kg/m2) and half of them were treated with GH (0.04 IU/kg) for 4 weeks in a randomized double-blind placebo-controlled study.
Report a problemFND-1091000307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.